[Statement of the DDG and the BVDD on the EMEA recommendations the use of raptiva [efalizumab]].
Luger
Thomas
T
Reusch
Michael
M
Reich
Kristian
K
Augustin
Matthias
M
Sterry
Wolfram
W
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003880:Dermatology / Q000592:standards*; D005858:Germany; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000188:drug therapy / Q000209:etiology; D017410:Practice Guidelines as Topic; D011565:Psoriasis / Q000188:drug therapy; D012955:Societies, Medical
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C472181:efalizumab